Boston Scientific Corp. (BSX) Tops Q2 EPS by 7c; Guides Q3 EPS Below, Reaffirms FY12
Boston Scientific Corp. (NYSE: BSX) reported Q2 EPS of $0.17, $0.07 better than the analyst estimate of $0.10. Revenue for the quarter came in at $1.83 billion versus the consensus estimate of $1.89 billion.
Boston Scientific Corp. sees Q3 2012 EPS of $0.14-$0.17, versus the consensus of $0.11. Boston Scientific Corp. sees Q3 2012 revenue of $1.725-$1.825 billion, versus the consensus of $1.83 billion.
Reaffirms FY12 outlook.
For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.
Boston Scientific Corp. sees Q3 2012 EPS of $0.14-$0.17, versus the consensus of $0.11. Boston Scientific Corp. sees Q3 2012 revenue of $1.725-$1.825 billion, versus the consensus of $1.83 billion.
Reaffirms FY12 outlook.
For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.